JB Chemicals & Pharmaceuticals Announces Q4 FY26 Results, Noting Operational Reset and Future Recovery

JB Chemicals & Pharmaceuticals Announces Q4 FY26 Results, Noting Operational Reset and Future Recovery​

JB Chemicals & Pharmaceuticals Limited announced its financial results for the fourth quarter of the fiscal year 2026. The company reported key figures for the quarter, highlighting a revenue of Rs. 904 crores and an EBITDA of Rs. 241 crores.

The financial results indicate a Gross Margin of 70% and an EBITDA margin of 27% for Q4 FY26. Net Profit after tax stood at Rs. 101 crores, while the adjusted net profit after tax, which adjusts for non-cash ESOP charges, exceptional, and one-off items, was Rs. 150 crores.

Quarterly and Full Year Performance Overview​

The company provided a detailed financial comparison covering Q4 FY26, Q4 FY25, and the full years FY26 and FY25.


*EBITDA and PAT figures are adjusted for specific items, including exceptional items and one-offs.

Segment Performance Analysis​

India Business:
The India business registered a year-over-year (YoY) growth of 2% during the quarter, reaching INR 526 crores. For the full year (FY26), the India business achieved 9% YoY growth, totaling INR 2,461 crores, with the BGx business growing 11%.

Analyst data from IQVIA MAT Mar'26 suggests the India business grew at 11% compared to an IPM growth of 10%. Notably, the chronic portfolio grew 19%, significantly outpacing the industry growth rate of 14%. Secondary market growth, as per IQVIA MAT March 26, was 11%, reflecting underlying growth for both the quarter and the full year.

International Formulations:
For the quarter, the International Business reported a de-growth of 9%, amounting to INR 259 crores. However, for FY26, international formulations revenue grew 2% YoY, achieving INR 1,154 crores. The business performance was impacted by the one-off negative effect of inventory rationalization, changes in credit practices linked to a change of control, and shipment delays due to container constraints in international markets.

CDMO:
CDMO revenues declined by 22% for the quarter, attributed to a high base recorded in the corresponding quarter of the previous year. The full year CDMO business remained flat at INR 445 crores, citing impact from previous years' high base and a reduction in inventory held by customers.

Future Outlook and Integration​

The company noted that the quarter represented a transient yet important phase of post-acquisition integration activities. These efforts involved aligning business policies, practices, and operating frameworks across the organization with those of the parent entity.

JB Chemicals & Pharmaceuticals Limited stated that the core business performance remains robust despite the operational realignment. The company believes these impacts are temporary and expects business performance to progressively improve in the coming quarters, starting from April. Management highlighted that the execution of cost synergies and uniform practice alignment is expected to drive further momentum, with further cost synergy execution for the upcoming year remaining on track.

JBCHEPHARM Stock Price Movement​

Today, JB Chemicals & Pharmaceuticals Limited shares edged higher to close at ₹2209.2, climbing 2.93% in post-market trading. The equity hit its 52-week high of ₹2224.9, with 584,031 shares trading volume recorded today.